The enigmatic helicase DHX9 and its association with the hallmarks of cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 34(15), 4206–4215 (2006).
  CASGoogle Scholar
• 2. Jain A, Bacolla A, Del Mundo IM, Zhao J, Wang G, Vasquez KM. DHX9 helicase is involved in preventing genomic instability induced by alternatively structured DNA in human cells. Nucleic Acids Res. 41(22), 10345–10357 (2013).
  CASGoogle Scholar
• 3. Cristini A, Groh M, Kristiansen MS, Gromak N. RNA/DNA hybrid interactome identifies DXH9 as a molecular player in transcriptional termination and R-loop-associated DNA damage. Cell Rep. 23(6), 1891–1905 (2018).
  CASGoogle Scholar
• 4. Cao S, Sun R, Wang W et al. RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin. Am. J. Transl. Res. 9(2), 674–682 (2017).
  CASGoogle Scholar
• 5. Yan X, Chang J, Sun R et al. DHX9 inhibits epithelial-mesenchymal transition in human lung adenocarcinoma cells by regulating STAT3. Am. J. Transl. Res. 11(8), 4881–4894 (2019).
  CASGoogle Scholar
• 6. Mi J, Ray P, Liu J et al. In vivo selection against human colorectal cancer xenografts identifies an aptamer that targets RNA helicase protein DHX9. Mol. Ther. - Nucleic Acids 5, e315 (2016).
  CASGoogle Scholar
• 7. Lee T, Pelletier J. The biology of DHX9 and its potential as a therapeutic target. Oncotarget 7(27), 42716–42739 (2016).
  Google Scholar
• 8. Umate P, Tuteja N, Tuteja R. Genome-wide comprehensive analysis of human helicases. Commun. Integr. Biol. 4(1), 118 (2011).
  CASGoogle Scholar
• 9. Gilman B, Tijerina P, Russell R. Distinct RNA-unwinding mechanisms of DEAD-box and DEAH-box RNA helicase proteins in remodeling structured RNAs and RNPs. Biochem. Soc. Trans. 45(6), 1313–1321 (2017).
  CASGoogle Scholar
• 10. Pyle AM. Translocation and unwinding mechanisms of RNA and DNA helicases. Annu. Rev. Biophys. 37(1), 317–336 (2008).
  CASGoogle Scholar
• 11. Schütz P, Karlberg T, van den Berg S et al. Comparative structural analysis of human DEAD-Box RNA helicases. PLoS ONE 5(9), e12791 (2010).
  Google Scholar
• 12. Bourgeois CF, Mortreux F, Auboeuf D. The multiple functions of RNA helicases as drivers and regulators of gene expression. Nat. Rev. Mol. Cell Biol. 17(7), 426–438 (2016).
  CASGoogle Scholar
• 13. Lee C-G, Eki T, Okumura K et al. The human RNA Helicase A (DDX9) gene maps to the prostate cancer susceptibility locus at chromosome band 1q25 and its pseudogene (DDX9P) to 13q22, respectively.Somat Cell Mol Genet 25(1), 33–39 (1999).
  CASGoogle Scholar
• 14. Zhang S, Grosse F. Domain structure of human nuclear DNA helicase II (RNA helicase A). J. Biol. Chem. 272(17), 11487–11494 (1997).
  CASGoogle Scholar
• 15. Fidaleo M, Svetoni F, Volpe E, Miñana B, Caporossi D, Paronetto MP. Genotoxic stress inhibits ewing sarcoma cell growth by modulating alternative pre-mRNA processing of the RNA helicase DHX9. Oncotarget 6(31), 31740–31757 (2015).
  Google Scholar
• 16. Chakraborty P, Grosse F. Human DHX9 helicase preferentially unwinds RNA-containing displacement loops (R-loops) and G-quadruplexes. DNA Repair (Amst). 10(6), 654–665 (2011).
  CASGoogle Scholar
• 17. Mikolaskova B, Jurcik M, Cipakova I, Kretova M, Chovanec M, Cipak L. Maintenance of genome stability: the unifying role of interconnections between the DNA damage response and RNA-processing pathways. Curr. Genet. 64(5), 971–983 (2018).
  CASGoogle Scholar
• 18. Roy D, Zhang Z, Lu Z, Hsieh C-L, Lieber MR. Competition between the RNA transcript and the nontemplate DNA strand during R-loop formation in vitro: a nick can serve as a strong R-loop initiation site. Mol. Cell. Biol. 30(1), 146–159 (2010).
  CASGoogle Scholar
• 19. Allison DF, Wang GG. R-loops: formation, function, and relevance to cell stress. Cell Stress. 3(2), 38–46 (2019).
  CASGoogle Scholar
• 20. Hamperl S, Bocek MJ, Saldivar JC, Swigut T, Cimprich KA. Transcription-replication conflict orientation modulates R-loop levels and activates distinct DNA damage responses. Cell 170(4), 774 (2017).
  CASGoogle Scholar
• 21. Gan W, Guan Z, Liu J et al. R-loop-mediated genomic instability is caused by impairment of replication fork progression. Genes Dev. 25(19), 2041–2056 (2011).
  CASGoogle Scholar
• 22. Fidaleo M, De Paola E, Paronetto MP. The RNA helicase A in malignant transformation. Oncotarget 7(19), 28711–28723 (2016).
  Google Scholar
• 23. Chakraborty P, Huang JTJ, Hiom K. DHX9 helicase promotes R-loop formation in cells with impaired RNA splicing. Nat. Commun. 9(1), 4346–4359 (2018).
  Google Scholar
• 24. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet. 19(3), 254–256 (1998).
  CASGoogle Scholar
• 25. Hatchi E, Skourti-Stathaki K, Ventz S et al. BRCA1 recruitment to transcriptional pause sites is required for R-loop-driven DNA damage repair. Mol. Cell. 57(4), 636–647 (2015).
  CASGoogle Scholar
• 26. Skourti-Stathaki K, Proudfoot NJ, Gromak N. Human senataxin resolves RNA/DNA hybrids formed at transcriptional pause sites to promote Xrn2-dependent termination. Mol. Cell. 42(6), 794–805 (2011).
  CASGoogle Scholar
• 27. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 22(1), 106 (2012).
  CASGoogle Scholar
• 28. Ohle C, Tesorero R, Schermann G, Dobrev N, Sinning I, Fischer T. Transient RNA-DNA hybrids are required for efficient double-strand break repair. Cell 167(4), 1001–1013.e7 (2016).
  CASGoogle Scholar
• 29. Yasuhara T, Kato R, Hagiwara Y et al. Human Rad52 promotes XPG-mediated R-loop processing to initiate transcription-associated homologous recombination repair. Cell 175(2), 558–570.e11 (2018).
  CASGoogle Scholar
• 30. Chakraborty P, Hiom K. DHX9-dependent recruitment of BRCA1 to RNA is required to promote DNA end resection in homologous recombination. bioRxiv. doi: https://doi.org/10.1101/2019.12.20.884593 (2019). •• Discusses linking DExH-Box helicase 9 (DHX9)’s role in R-loop resolution and BRCA1 recruitment to mediating DNA damage repair and genomic stability.
  Google Scholar
• 31. Skourti-Stathaki K, Proudfoot NJ. A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. Genes Dev. 28(13), 1384–1396 (2014).
  CASGoogle Scholar
• 32. Friedemann J, Grosse F, Zhang S. Nuclear DNA helicase II (RNA helicase A) interacts with Werner syndrome helicase and stimulates its exonuclease activity. J. Biol. Chem. 280(35), 31303–31313 (2005).
  CASGoogle Scholar
• 33. Chakraborty P, Grosse F. WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicase. Nucleic Acids Res. 38(14), 4722–4730 (2010).
  CASGoogle Scholar
• 34. Lee T, Di Paola D, Malina A et al. Suppression of the DHX9 helicase induces premature senescence in human diploid fibroblasts in a p53-dependent manner. J. Biol. Chem. 289(33), 22798–22814 (2014).
  CASGoogle Scholar
• 35. Duquette ML, Handa P, Vincent JA, Taylor AF, Maizels N. Intracellular transcription of G-rich DNAs induces formation of G-loops, novel structures containing G4 DNA. Genes Dev. 18(13), 1618 (2004).
  CASGoogle Scholar
• 36. Myöhänen S, Baylin SB. Sequence-specific DNA binding activity of RNA helicase A to the p16INK4a promoter. J. Biol. Chem. 276(2), 1634–1642 (2001).
  CASGoogle Scholar
• 37. Zhong X, Safa AR. Phosphorylation of RNA helicase a by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrag-resistant human leukemia cells. Biochemistry 46(19), 5766–5775 (2007).
  CASGoogle Scholar
• 38. Huo L, Wang YN, Xia W et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc. Natl Acad. Sci. USA 107(37), 16125–16130 (2010).
  CASGoogle Scholar
• 39. Monteiro AN. BRCA1: exploring the links to transcription. Trends Biochem. Sci. 25(10), 469–474 (2000).
  CASGoogle Scholar
• 40. Nakajima T, Uchida C, Anderson SF et al. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90(6), 1107–1112 (1997).
  CASGoogle Scholar
• 41. Tetsuka T, Uranishi H, Sanda T et al. RNA helicase A interacts with nuclear factor κB p65 and functions as a transcriptional coactivator. Eur. J. Biochem. 271(18), 3741–3751 (2004).
  CASGoogle Scholar
• 42. Mukherjee SP, Behar M, Birnbaum HA, Hoffmann A, Wright PE, Ghosh G. Analysis of the RelA:CBP/p300 interaction reveals its involvement in NF-κB-driven transcription. PLoS Biol. 11(9), e1001647 (2013).
  CASGoogle Scholar
• 43. Parsyan A, Svitkin Y, Shahbazian D et al. mRNA helicases: the tacticians of translational control. Nat. Rev. Mol. Cell Biol. 12(4), 235–245 (2011).
  CASGoogle Scholar
• 44. Murat P, Marsico G, Herdy B, Ghanbarian A, Portella G, Balasubramanian S. RNA G-quadruplexes at upstream open reading frames cause DHX36- and DHX9-dependent translation of human mRNAs. Genome Biol. 19(1), 229 (2018).
  CASGoogle Scholar
• 45. Hartman TR, Qian S, Bolinger C, Fernandez S, Schoenberg DR, Boris-Lawrie K. RNA helicase A is necessary for translation of selected messenger RNAs. Nat. Struct. Mol. Biol. 13(6), 509–516 (2006).
  CASGoogle Scholar
• 46. Robb GB, Rana TM. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol. Cell 26(4), 523–537 (2007).
  CASGoogle Scholar
• 47. Fu Q, Yuan YA. Structural insights into RISC assembly facilitated by dsRNA-binding domains of human RNA helicase A (DHX9). Nucleic Acids Res. 41(5), 3457 (2013).
  CASGoogle Scholar
• 48. Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J. Cell Biol. 197(2), 201–208 (2012).
  CASGoogle Scholar
• 49. Boeras I, Song Z, Moran A et al. DHX9/RHA binding to the PBS-segment of the genomic RNA during HIV-1 assembly bolsters virion infectivity. J. Mol. Biol. 428(11), 2418–2429 (2016).
  CASGoogle Scholar
• 50. Ng YC, Chung WC, Kang HR et al. A DNA-sensing–independent role of a nuclear RNA helicase, DHX9, in stimulation of NF-B–mediated innate immunity against DNA virus infection. Nucleic Acids Res. 46(17), 9011–9026 (2018).
  CASGoogle Scholar
• 51. Kim T, Pazhoor S, Bao M et al. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc. Natl Acad. Sci. USA 107(34), 15181–15186 (2010).
  CASGoogle Scholar
• 52. Zhang Z, Yuan B, Lu N, Facchinetti V, Liu Y-J. DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J. Immunol. 187(9), 4501 (2011).
  CASGoogle Scholar
• 53. Shen B, Chen Y, Hu J et al. Hepatitis B virus X protein modulates upregulation of DHX9 to promote viral DNA replication. Cell. Microbiol. 22(3), e13148–57 (2020).
  CASGoogle Scholar
• 54. Chen Y, Shen B, Zheng X et al. DHX9 interacts with APOBEC3B and attenuates the anti-HBV effect of APOBEC3B. Emerg. Microbes Infect. 9(1), 366–377 (2020).
  CASGoogle Scholar
• 55. He QS, Tang H, Zhang J, Truong K, Wong-Staal F, Zhou D. Comparisons of RNAi approaches for validation of human RNA helicase A as an essential factor in hepatitis C virus replication. J. Virol. Methods 154(1–2), 216–219 (2008).
  CASGoogle Scholar
• 56. Bolinger C, Sharma A, Singh D, Yu L, Boris-Lawrie K. RNA helicase A modulates translation of HIV-1 and infectivity of progeny virions. Nucleic Acids Res. 38(5), 1686–1696 (2010).
  CASGoogle Scholar
• 57. Matkovic R, Bernard E, Fontanel S et al. The host DHX9 DExH-box helicase is recruited to chikungunya virus replication complexes for optimal genomic RNA translation. J. Virol. 93(4), e01764–18 (2019).
  CASGoogle Scholar
• 58. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011). • Describes the hallmarks of cancer and being the focus for this review article.
  CASGoogle Scholar
• 59. Wang YL, Liu JY, Yang JE et al. Lnc-UCID promotes G1/S transition and hepatoma growth by preventing DHX9-mediated CDK6 down-regulation. Hepatology 70(1), 259–275 (2019).
  CASGoogle Scholar
• 60. Lee EYHP, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb. Perspect. Biol. 2(10), a003236–53 (2010).
  CASGoogle Scholar
• 61. Pearson PL, Van der Luijt RB. The genetic analysis of cancer. J. Intern. Med. 243(6), 413–417 (1998).
  CASGoogle Scholar
• 62. Wells JP, White J, Stirling PC. R loops and their composite cancer connections. Trends in Cancer 5(10), 619–631 (2019).
  CASGoogle Scholar
• 63. Turanli B, Karagoz K, Bidkhori G et al. Multi-omic data interpretation to repurpose subtype specific drug candidates for breast cancer. Front. Genet. 10, 420–32 (2019).
  CASGoogle Scholar
• 64. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS. Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 69(2), 709 (2009).
  CASGoogle Scholar
• 65. Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Res. Treat. 162(3), 439 (2017).
  CASGoogle Scholar
• 66. Liu P, Ramachandran S, Ali Seyed M et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66(8), 4011–4019 (2006).
  CASGoogle Scholar
• 67. Moreno CS. SOX4: the unappreciated oncogene. Semin. Cancer Biol. (18), 30145–7 (2019).
  Google Scholar
• 68. Lai YH, Cheng J, Cheng D et al. SOX4 interacts with plakoglobin in a Wnt3a-dependent manner in prostate cancer cells. BMC Cell Biol. 12, 50–57 (2011).
  CASGoogle Scholar
• 69. Zandi R, Larsen AB, Andersen P, Stockhausen M-T, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013–2023 (2007).
  CASGoogle Scholar
• 70. Lin S-Y, Makino K, Xia W et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 3(9), 802–808 (2001).
  CASGoogle Scholar
• 71. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 14(19), 2393–2409 (2000).
  CASGoogle Scholar
• 72. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78(3), 323–35 (2003).
  CASGoogle Scholar
• 73. Garcea G, Neal C, Pattenden C, Steward W, Berry D. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 41(15), 2213–2236 (2005).
  CASGoogle Scholar
• 74. Gautschi O, Ratschiller D, Gugger M, Betticher D, Heighway J. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 55(1), 1–14 (2007).
  Google Scholar
• 75. Palombo R, Frisone P, Fidaleo M, Mercatelli N, Sette C, Paronetto MP. The promoter-associated noncoding RNA PNCCCND1_B assembles a protein–RNA complex to regulate cyclin D1 transcription in Ewing sarcoma. Cancer Res. 79(14), 3570–3582 (2019).
  CASGoogle Scholar
• 76. Li J, Poi MJ, Tsai M-D. The regulatory mechanisms of tumor supressor p16INK4 and relevance to cancer. Biochemistry 50(25), 5566–5582 (2011).
  CASGoogle Scholar
• 77. Schlegel BP, Starita LM, Parvin JD. Overexpression of a protein fragment of rna helicase a causes inhibition of endogenous brca1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene 22(7), 983–991 (2003).
  CASGoogle Scholar
• 78. Deng C-X. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34(5), 1416 (2006).
  CASGoogle Scholar
• 79. Aprelikova ON, Fang BS, Meissner EG et al. BRCA1-associated growth arrest is RB-dependent. Proc. Natl Acad. Sci. USA 96(21), 11866 (1999).
  CASGoogle Scholar
• 80. Guénard F, Labrie Y, Ouellette G et al. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer. J. Hum. Genet. 54(3), 152–161 (2009).
  CASGoogle Scholar
• 81. Furuta S, Jiang X, Gu B, Cheng E, Chen P, Lee W. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc. Natl Acad. Sci. USA 102(26), 9176–9181 (2005).
  CASGoogle Scholar
• 82. Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers (Basel) 3(1), 994–1013 (2011).
  CASGoogle Scholar
• 83. Lee T, Paquet M, Larsson O, Pelletier J. Tumor cell survival dependence on the DHX9 DExH-box helicase. Oncogene 35(39), 5093–5105 (2016). •• Reveals safety and efficacy of targeting DHX9.
  CASGoogle Scholar
• 84. Lee T, Pelletier J. Dependence of p53-deficient cells on the DHX9 DExH-box helicase. Oncotarget 8(19), 30908–30921 (2017).
  Google Scholar
• 85. Chen ZX, Wallis K, Fell SM et al. RNA helicase a is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma. Cancer Discov. 4(4), 434–451 (2014).
  CASGoogle Scholar
• 86. Ding X, Jia X, Wang C, Xu J, Gao S-J, Lu C. A DHX9-lncRNA-MDM2 interaction regulates cell invasion and angiogenesis of cervical cancer. Cell Death Differ. 26(9), 1750–1765 (2019).
  CASGoogle Scholar
• 87. Hansen T, Jensen T, Clausen B et al. Natural RNA circles function as efficient microRNA sponges. Nature 495(7441), 384–388 (2013).
  CASGoogle Scholar
• 88. Aktaş T, Ilik IA, Maticzka D et al. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature 544(7648), 115–119 (2017).
  CASGoogle Scholar
• 89. Hsiao K-Y, Lin Y-C, Gupta SK et al. Non-coding effects of circular RNA CCDC66 promote colon cancer growth and metastasis. Cancer Res. 77(9), 2339 (2017).
  CASGoogle Scholar
• 90. Lin Y, Yu Y, Lin H, Hsiao K. Oxaliplatin-induced DHX9 phosphorylation promotes oncogenic circular RNA CCDC66 expression and development of chemoresistance. Cancers (Basel) 12(3), 1–14 (2020).
  Google Scholar
• 91. Yu J, Xu Q-G, Wang Z-G et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. J. Hepatol. 68(6), 1214–1227 (2018).
  CASGoogle Scholar
• 92. Zucchini C, Rocchi A, Manara MC et al. Apoptotic genes as potential markers of metastatic phenotype in human osteosarcoma cell lines. Int. J. Oncol. 32(1), 17–31 (2008).
  CASGoogle Scholar
• 93. Song Z, Zhuo Z, Ma Z, Hou C, Chen G, Xu G. Hsa_Circ_0001206 is downregulated and inhibits cell proliferation, migration and invasion in prostate cancer. Artif. Cells, Nanomedicine, Biotechnol. 47(1), 2449–2464 (2019).
  CASGoogle Scholar
• 94. Kamelgarn M, Chen J, Kuang L et al. Proteomic analysis of FUS interacting proteins provides insights into FUS function and its role in ALS. Biochim. Biophys. Acta 1862(10), 2004–2014 (2016).
  CASGoogle Scholar
• 95. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 15(2), 117 (2010).
  Google Scholar
• 96. Shang B-Q, Li M-L, Quan H et al. Functional roles of circular RNAs during epithelial-to-mesenchymal transition. Mol. Cancer 18, 138–147 (2019).
  Google Scholar
• 97. Yan D, Dong W, He Q et al. Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation. EBioMedicine 48, 316–331 (2019).
  Google Scholar
• 98. Joseph NA, Chiou S-H, Lung Z et al. The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. J. Hematol. Oncol. 11, 557–559 (2018).
  Google Scholar
• 99. Wang W-P, Sun Y, Lu Q et al. Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/STAT3 and TGF-β/SMAD3 signaling pathway. Oncotarget 8(4), 5909–5923 (2017).
  Google Scholar
• 100. Woods D, Turchi JJ. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol. Ther. 14(5), 379–389 (2013).
  CASGoogle Scholar
• 101. Nogales V, Reinhold WC, Varma S et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 7(3), 3084–3097 (2016).
  Google Scholar
• 102. Zhong X, Safa AR. RNA helicase A in the MEF1 transcription factor complex up-regulates the MDR1 gene in multidrug-resistant cancer cells. J. Biol. Chem. 279(17), 17134–17141 (2004).
  CASGoogle Scholar
• 103. Yi G-Z, Xiang W, Feng W-Y et al. Identification of key candidate proteins and pathways associated with temozolomide resistance in glioblastoma based on subcellular proteomics and bioinformatical analysis. Biomed Res. Int. 2018, 5238760 (2018).
  Google Scholar
• 104. Boros-Oláh B, Dobos N, Hornyák L et al. Drugging the R-loop interactome: RNA-DNA hybrid binding proteins as targets for cancer therapy. DNA Repair (Amst). 84, 102642–52 (2019).
  CASGoogle Scholar
• 105. Chesler L, Goldenberg DD, Collins R et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10(11), 1268–1274 (2008).
  CASGoogle Scholar
• 106. Mills JR, Malina A, Lee T et al. RNAi screening uncovers DHX9 as a modifier of ABT-737 resistance in an Em-myc/BCL-2 mouse model. Blood 121(17), 3402–3412 (2013).
  CASGoogle Scholar
• 107. Toretsky JA, Erkizan V, Levenson A et al. Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res. 66(11), 5574–5581 (2006).
  CASGoogle Scholar
• 108. Palombo R, Verdile V, Paronetto MP. Poison-exon inclusion in DHX9 reduces its expression and sensitizes Ewing sarcoma cells to chemotherapeutic treatment. Cells 9(2), 328 (2020).
  CASGoogle Scholar
• 109. Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int. J. Oncol. 54(2), 407–419 (2019).
  CASGoogle Scholar
• 110. Lee CG, Da Costa Soares V, Newberger C, Manova K, Lacy E, Hurwitz J. RNA helicase A is essential for normal gastrulation. Proc. Natl Acad. Sci. USA 95(23), 13709–13713 (1998).
  CASGoogle Scholar
• 111. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2(4), 466 (2011).
  CASGoogle Scholar
• 112. Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer 18, 1086–1088 (2018).
  Google Scholar
• 113. Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J. Immunother. Cancer 6(1), 140 (2018).
  Google Scholar
• 114. Chesney J, Puzanov I, Collichio F et al. Randomized, open-label Phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J. Clin. Oncol. 36(17), 1658–1667 (2018).
  CASGoogle Scholar
• 115. Ribas A, Dummer R, Puzanov I et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(6), 1109–1119.e10 (2017).
  CASGoogle Scholar
• 116. Chan WM, Rahman MM, McFadden G. Oncolytic myxoma virus: the path to clinic. Vaccine 31(39), 4252–4258 (2013).
  Google Scholar
• 117. Rahman MM, Madlambayan GJ, Cogle CR, McFadden G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev. 21(2–3), 169–175 (2010).
  CASGoogle Scholar
• 118. Rahman MM, Bagdassarian E, Ali MAM, McFadden G. Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells. Sci. Rep. 7(1), 1–14 (2017).
  Google Scholar
• 119. Rahman MM, Liu J, Chan WM, Rothenburg S, McFadden G. Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication. PLoS Pathog. 9(7), e1003465 (2013).
  CASGoogle Scholar
• 120. Sadler AJ, Latchoumanin O, Hawkes D, Mak J, Williams BRG. An antiviral response directed by PKR phosphorylation of the RNA helicase A. PLoS Pathog. 5(2), e1000311 (2009).
  Google Scholar